New OSCAR Clinical Trial for potential COVID-19 therapy at UC Davis Health
Trial will test otilimab as a treatment for severe lung disease
UC Davis Health has been selected as a site for a new clinical trial (OSCAR) to test otilimab as a potential treatment for severe pulmonary COVID-19-related disease.
Otilimab, a human monoclonal antibody, was under investigation as a treatment for rheumatoid arthritis. Now, the OSCAR clinical trial will evaluate the efficacy and safety of a single infusion of otilimab in treating severe lung inflammation in COVID-19 patients.